Brooklyn ImmunoTherapeutics (NYSE:BTX) Shares Down 0.1% – Here’s Why

Brooklyn ImmunoTherapeutics Inc (NYSE:BTX)’s stock price dropped 0.1% during mid-day trading on Monday . The company traded as low as $7.06 and last traded at $7.13. Approximately 564,560 shares traded hands during mid-day trading, a decline of 24% from the average daily volume of 743,693 shares. The stock had previously closed at $7.14.

Wall Street Analyst Weigh In

Separately, Wall Street Zen initiated coverage on shares of Brooklyn ImmunoTherapeutics in a report on Saturday, May 17th. They set a “hold” rating for the company.

Brooklyn ImmunoTherapeutics Price Performance

The company has a market capitalization of $419.43 million, a P/E ratio of -3.14 and a beta of 4.61. The stock’s 50 day simple moving average is $6.42 and its two-hundred day simple moving average is $3.82.

About Brooklyn ImmunoTherapeutics

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.